Effectiveness of Aspirin on Major COPD Outcomes: A Prevalent New-User Design Observational Study

References

• Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):1–9. doi: 10.1016/S0140-6736(22)00470-6.
   PubMed Web of Science ®Google Scholar
• Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi: 10.1016/S2213-2600(21)00511-7.
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646. doi: 10.1378/chest.128.4.2640.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. doi: 10.1016/j.jacc.2006.04.039.
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48. doi: 10.1186/1471-2466-12-48.
   PubMedGoogle Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi: 10.1056/NEJMoa1403086.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. doi: 10.1056/NEJMoa1908142.
   PubMed Web of Science ®Google Scholar
• Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7. doi: 10.1159/000315387.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Beta-blockers in COPD: a methodological review of the observational studies. COPD. 2018;15(5):520–525. doi: 10.1080/15412555.2018.1554637.
   PubMedGoogle Scholar
• Sule NO, Suissa S. Statins and mortality in COPD: a methodological review of observational studies. COPD J. 2023;20(1):284–291. doi: 10.1080/15412555.2023.2242489.
   PubMedGoogle Scholar
• Campo G, Pavasini R, Malagù M, et al. Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD. COPD. 2015;12(5):560–567. doi: 10.3109/15412555.2014.995293.
   PubMedGoogle Scholar
• Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720. doi: 10.1164/rccm.201208-1565OC.
   PubMed Web of Science ®Google Scholar
• Ellingsen J, Johansson G, Larsson K, et al. Impact of comorbidities and commonly used drugs on mortality in COPD – Real-world data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–245. doi: 10.2147/COPD.S231296.
   PubMed Web of Science ®Google Scholar
• Fawzy A, Putcha N, Aaron CP, et al. Aspirin use and respiratory morbidity in COPD: a propensity score-matched analysis in subpopulations and intermediate outcome measures in COPD study. Chest. 2019;155(3):519–527. doi: 10.1016/j.chest.2018.11.028.
   PubMed Web of Science ®Google Scholar
• Goto T, Faridi MK, Camargo CA, et al. The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. NPJ Prim Care Respir Med. 2018;28(1):7. doi: 10.1038/s41533-018-0074-x.
   PubMedGoogle Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. doi: 10.1136/thoraxjnl-2013-203996.
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SIW, Elder DHJ, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342(2):d2549–d2549. doi: 10.1136/bmj.d2549.
   PubMedGoogle Scholar
• Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283. doi: 10.1183/09031936.00106406.
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, d’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. doi: 10.3109/15412555.2015.1099620.
   PubMedGoogle Scholar
• Sin DD. The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD? Thorax BMJ Publishing Group Ltd. 2014;69(7):603–604. doi: 10.1136/thoraxjnl-2014-205329.
   PubMed Web of Science ®Google Scholar
• Bakshi A, Suissa S. Effectiveness of aspirin in COPD: biases in the observational studies. COPD. 2021;18(4):449–455. doi: 10.1080/15412555.2021.1963696.
   PubMedGoogle Scholar
• Stein BD, Bautista A, Schumock GT, et al. The validity of international classification of diseases, ninth revision, clinical modification diagnosis codes for identifying patients hospitalized for COPD exacerbations. Chest. 2012;141(1):87–93. doi: 10.1378/chest.11-0024.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi: 10.1164/rccm.201710-2029OC.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PloS One. 2016;11(3):e0151357. doi: 10.1371/journal.pone.0151357.
   PubMed Web of Science ®Google Scholar
• Coates AL, Wong SL, Tremblay C, et al. Reference equations for spirometry in the Canadian population. Ann Am Thorac Soc. 2016;13(6):833–841. doi: 10.1513/AnnalsATS.201508-569OC.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499. doi: 10.1093/aje/kwm324.
   PubMed Web of Science ®Google Scholar
• Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol. 2010;39(2):417–420. doi: 10.1093/ije/dyp334.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–1518. doi: 10.1056/NEJMoa1805819.
   PubMed Web of Science ®Google Scholar
• Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLOS One. 2012;7(5):e37483. doi: 10.1371/journal.pone.0037483.
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100(8):793–798. doi: 10.1161/01.cir.100.8.793.
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Randomized trial to determine effective aspirin dose in COPD [Internet]. clinicaltrials.gov; 2023 MayReport No.: NCT05265299. https://clinicaltrials.gov/study/NCT05265299.
   Google Scholar